Video: Logistics Leaders: Specialty pharmaceuticals vs cell and gene therapy supply chain

By Sam Herbert |

The key difference in cell and gene therapy is that the patient is in the supply chain. Find out more from Sam Herbert, President of World Courier. 

Video Transcript:

The key difference in cell and gene therapy is the patient is in the supply chain. Traditional small and large molecules use bulk manufacturing, whereas in cell and gene therapy, we're often extracting cells from the patient, moving them through a customized manufacturing process, and then infusing them back into the patient. These patients are often very sick and often close to death, so it really requires us going through elaborate contingency planning and us designing a customized solution that meets our manufacturer's needs.

About the Author

Sam Herbert

President, World Courier & ICS
World Courier & ICS 
Sam leads the World Courier business, spanning more than 140 company-owned offices in 50+ countries. Prior to his role as President, Herbert was Chief Operating Officer, responsible for World Courier’s global functions. Before joining World Courier in 2013 as Vice President of Strategy, Herbert was a partner in Oliver Wyman's Health and Life Sciences practice where he advised some of the world's leading pharmaceutical, healthcare and pharmaceutical services companies, including AmerisourceBergen. Herbert holds an AB of Economics, cum laude, from Harvard College and is based in World Courier's global headquarters in London.
View Bio